You are here

  • Home
  • Archive
  • Volume 12, Issue 6
  • Blinatumomab as postremission therapy replaces consolidation and substantial parts of maintenance chemotherapy and results in stable MRD negativity in children with newly diagnosed B-lineage ALL

Article metrics

Article menu
Clinical/translational cancer immunotherapy
Blinatumomab as postremission therapy replaces consolidation and substantial parts of maintenance chemotherapy and results in stable MRD negativity in children with newly diagnosed B-lineage ALL

 

Online download statistics by month:

Online download statistics by month: June 2024 to October 2025

AbstractFullPdf
Jun 2024909910249
Jul 2024278283133
Aug 202417517589
Sep 202416116287
Oct 2024169169107
Nov 2024186188108
Dec 202415916397
Jan 202513113587
Feb 202523123387
Mar 202513613671
Apr 2025200200110
May 202513413491
Jun 2025939448
Jul 2025110
Sep 2025550
Oct 2025111
Total296929891365